NuPathe Inc. clinical trials
Acquired by Teva Pharmaceutical Industries, Ltd., Feb 21, 2014 · source ↗
The registry lists 8 studies whose lead sponsor is NuPathe Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 12, 2017.
- 8studies on the registry
- 0open to participants now
Before and after it joined Teva Pharmaceutical Industries, Ltd.
- First submitted before NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- 7
- First submitted after NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs NuPathe Inc.’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Sumatriptan3 in phase 30 open · 8
- Black Seed Oil Extract Supplement2 in phase 30 open · 5
- Nigella sativa oil2 in phase 30 open · 5
All 8 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed8100%
Over the years
- 07
- 08
- 409
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- NuPathe Inc.8 studies
Something wrong with this grouping? Tell us on the Teva Pharmaceutical Industries, Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Teva Pharmaceutical Industries, Ltd. studies →
- Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy AdultsCompletedNCT01381796Phase 1
Sponsor listed in the registry: NuPathe Inc. · First submitted before NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute MigraineCompletedNCT02684409Phase 1
Sponsor listed in the registry: NuPathe Inc. · First submitted after NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve MonthsCompletedNCT00806546Phase 3
Sponsor listed in the registry: NuPathe Inc. · First submitted before NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 MonthsCompletedNCT00792103Phase 3
Sponsor listed in the registry: NuPathe Inc. · First submitted before NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute MigraineCompletedNCT00724815Phase 3
Sponsor listed in the registry: NuPathe Inc. · First submitted before NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®CompletedNCT00546650Phase 1
Sponsor listed in the registry: NuPathe Inc. · First submitted before NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy VolunteersCompletedNCT00720018Phase 1
Sponsor listed in the registry: NuPathe Inc. · First submitted before NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.
- Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine PeriodCompletedNCT00723983Phase 1
Sponsor listed in the registry: NuPathe Inc. · First submitted before NuPathe Inc. became part of Teva Pharmaceutical Industries, Ltd.